AEZS-108: a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors

Bibliography

• Schally AV, Engel JB, Emons G, Use of analogs of peptide hormones conjugated to cytotoxic radicals for chemotherapy targeted to receptors on tumors. Curr Drug Deliv 2011;8:11-25
   PubMed Web of Science ®Google Scholar
• Engel JB, Schally AV. Drug Insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone. Nat Clin Pract Endocrinol Metab 2007;3:157-67
   PubMedGoogle Scholar
• Schally AV, Comaru-Schally AM, Nagy A, Hypothalamic hormones and cancer. Front Neuroendocrinol 2001;22:248-91
   PubMed Web of Science ®Google Scholar
• Schally AV, Nagy A. Chemotherapy targeted to cancers through tumoral hormone receptors. Trends Endocrinol Metab 2004;15:300-10
   PubMed Web of Science ®Google Scholar
• Nagy A, Plonowski A, Schally AV. Stability of cytotoxic luteinizing hormone-releasing hormone conjugate (AN-152) containing doxorubicin 14-O-hemiglutarate in mouse and human serum in vitro: implications for the design of preclinical studies. Proc Natl Acad Sci USA 2000;97:829-34
   PubMed Web of Science ®Google Scholar
• Nagy A, Schally AV, Armatis P, Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent. Proc Natl Acad Sci USA 1996;93:7269-73
   PubMed Web of Science ®Google Scholar
• Halmos G, Nagy A, Lamharzi N, Schally AV. Cytotoxic analogs of luteinizing hormone-releasing hormone bind with high affinity to human breast cancers. Cancer Lett 1999;136(2):129-36
   PubMed Web of Science ®Google Scholar
• Westphalen S, Kotulla G, Kaiser F, Receptor mediated antiproliferative effects of the cytotoxic LHRH agonist AN-152 in human ovarian and endometrial cancer cell lines. Int J Oncol 2000;17:1063-9
   PubMed Web of Science ®Google Scholar
• Gunthert AR, Grundker C, Bongertz T, Internalization of cytotoxic analog AN-152 of luteinizing hormone-releasing hormone induces apoptosis in human endometrial and ovarian cancer cell lines independent of multidrug resistance-1 (MDR-1) system. Am J Obstet Gynecol 2004;191:1164-72
   PubMed Web of Science ®Google Scholar
• Grundker C, Volker P, Griesinger F, Antitumor effects of the cytotoxic luteinizing hormone-releasing hormone analog AN-152 on human endometrial and ovarian cancers xenografted into nude mice. Am J Obstet Gynecol 2002;187:528-37
   PubMed Web of Science ®Google Scholar
• Schally AV, Nagy A. New approaches to treatment of various cancers based on cytotoxic analogs of LHRH, somatostatin and bombesin. Life Sci 2003;72:2305-20
   PubMed Web of Science ®Google Scholar
• Emons G, Sindermann H, Engel J, Luteinizing hormone-releasing hormone receptor-targeted chemotherapy using AN-152. Neuroendocrinology 2009;90:15-18
   PubMed Web of Science ®Google Scholar
• Engel JB, Schally AV, Dietl J, Targeted therapy of breast and gynecological cancers with cytotoxic analogues of peptide hormones. Mol Pharm 2007;4:652-8
   PubMed Web of Science ®Google Scholar
• Fekete M, Wittliff JL, Schally AV. Characteristics and distribution of receptors for [D-TRP6]-luteinizing hormone-releasing hormone, somatostatin, epidermal growth factor, and sex steroids in 500 biopsy samples of human breast cancer. J Clin Lab Anal 1989;3:137-47
   PubMed Web of Science ®Google Scholar
• Bajo AM, Schally AV, Halmos G, Nagy A. Targeted doxorubicin-containing luteinizing hormone-releasing hormone analogue AN-152 inhibits the growth of doxorubicin-resistant MX-1 human breast cancers. Clin Cancer Res 2003;9:3742-8
   PubMed Web of Science ®Google Scholar
• Kahan Z, Nagy A, Schally AV, Administration of a targeted cytotoxic analog of luteinizing hormone-releasing hormone inhibits growth of estrogen-independent MDA-MB-231 human breast cancers in nude mice. Breast Cancer Res Treat 2000;59:255-62
   PubMed Web of Science ®Google Scholar
• Buchholz S, Seitz S, Schally AV, Triple-negative breast cancers express receptors for luteinizing hormone-releasing hormone (LHRH) and respond to LHRH antagonist Cetrorelix with growth inhibition. Int J Oncol 2009;35:789-96
   Google Scholar
• Foest C, Duwe F, Hellriegel M, Targeted chemotherapy for triple-negative breast cancers via LHRH receptor. Oncol Rep 2011;25:1481-7
   PubMed Web of Science ®Google Scholar
• Emons G, Ortmann O, Becker M, High affinity binding and direct antiproliferative effects of LHRH analogues in human ovarian cancer cell lines. Cancer Res 1993;53:5439-46
   PubMed Web of Science ®Google Scholar
• Emons G, Pahwa GS, Brack C, Gonadotropin releasing hormone binding sites in human epithelial ovarian carcinomata. Eur J Cancer Clin Oncol 1989;25:215-21
   PubMedGoogle Scholar
• Srkalovic G, Schally AV, Wittliff JL, Presence and characteristics of receptors for [D-Trip6]luteinizing hormone releasing hormone and epidermal growth factor in human ovarian cancer. Int J Oncol 1998;12:489-98
   PubMed Web of Science ®Google Scholar
• Volker P, Grundker C, Schmidt O, Expression of receptors for luteinizing hormone-releasing hormone in human ovarian and endometrial cancers: frequency, autoregulation, and correlation with direct antiproliferative activity of luteinizing hormone-releasing hormone analogues. Am J Obstet Gynecol 2002;186:171-9
   PubMed Web of Science ®Google Scholar
• Miyazaki M, Nagy A, Schally AV, Growth inhibition of human ovarian cancers by cytotoxic analogues of luteinizing hormone-releasing hormone. J Natl Cancer Inst 1997;89:1803-9
   PubMed Web of Science ®Google Scholar
• Arencibia JM., Schally AV, Krupa M, Targeting of doxorubicin to ES-2 human ovarian cancers in nude mice by linking to an analog of luteinizing hormone-releasing hormone improves its effectiveness. Int J Oncol 2001;19:571-7
   PubMed Web of Science ®Google Scholar
• Srkalovic G, Wittliff JL, Schally AV. Detection and partial characterization of receptors for [D-Trp6]-luteinizing hormone-releasing hormone and epidermal growth factor in human endometrial carcinoma. Cancer Res 1990;50:1841-6
   PubMed Web of Science ®Google Scholar
• Emons G, Schroder B, Ortmann O, High affinity binding and direct antiproliferative effects of luteinizing hormone-releasing hormone analogs in human endometrial cancer cell lines. J Clin Endocrinol Metab 1993;77:1458-64
   PubMed Web of Science ®Google Scholar
• Engel JB, Keller G, Schally AV, Effective treatment of experimental human endometrial cancers with targeted cytotoxic luteinizing hormone-releasing hormone analogues AN-152 and AN-207. Fertil Steril 2005;83(Suppl 1):1125-33
   PubMedGoogle Scholar
• Halmos G, Arencibia JM, Schally AV, High incidence of receptors for luteinizing hormone-releasing hormone (LHRH) and LHRH receptor gene expression in human prostate cancers. J Urol 2000;163:623-9
   PubMed Web of Science ®Google Scholar
• Liu S, Schally AV, Hawes D, Expression of receptors for luteinizing hormone-releasing hormone (LH-RH) in prostate cancer following therapy with LH-RH agonists. Clin Cancer Res 2010;16(18):4675-80
   PubMed Web of Science ®Google Scholar
• Letsch M, Schally AV, Szepeshazi K, Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers. Clin Cancer Res 2003;9:4505-13
   PubMed Web of Science ®Google Scholar
• Fekete M, Zalatnai A, Schally AV. Presence of membrane binding sites for [D-TRP6]-luteinizing hormone-releasing hormone in experimental pancreatic cancer. Cancer Lett 1989;45:87-91
   PubMed Web of Science ®Google Scholar
• Gruendker C, Ernst J, Reutter MD, Effective targeted chemotherapy using AEZS-108 (AN-152) for LHRH receptor-positive pancreatic cancers. Oncol Rep 2011;26:629-35
   PubMed Web of Science ®Google Scholar
• Buchholz S, Keller G, Schally AV, Therapy of ovarian cancers with targeted cytotoxic analogs of bombesin, somatostatin, and luteinizing hormone-releasing hormone and their combinations. PNAS 2006;103(27):10403-7
   PubMed Web of Science ®Google Scholar
• Guenther E, Teifel M, Engel JB, Targeting doxorubicin to LHRH-receptor positive tumors by the cytotoxic hybrid ZEN-008 (AN-152). EJC Suppl 2006;4(12):159
   Web of Science ®Google Scholar
• Emons G, Kaufmann M, Gorchev G, Dose escalation and pharmacokinetic study of AEZS-108 (AN-152), an LHRH agonist linked to doxorubicin, in women with LHRH receptor-positive tumors. Gynecol Oncol 2010;119:457-61
   PubMed Web of Science ®Google Scholar
• Emons G, Tomov S, Harter P, Phase II study of AEZS-108 (AN-152), a targeted cytotoxic LHRH analog, in patients with LHRH receptor-positive platinum resistant ovarian cancer. J Clin Oncol ASCO Meeting abstr 2010;28(15 part 1):abstract 5035
   Google Scholar
• Emons G, Sehouli J, Gorchev G, Phase II study of AEZS-108 (AN-152), a targeted cytotoxic LHRH analog, in patients with LHRH receptor positive endometrial cancer. EJC Suppl 2010;8/7:120
   Web of Science ®Google Scholar
• Liu SV, Liu S, Pinski J. Luteinizing hormone-releasing hormone receptor targeted agents for prostate cancer. Expert Opin Investig Drugs 2011;20/6:769-78
   Web of Science ®Google Scholar
• Liu SV, Schally AV, Dorff T, A phase I/II trial of AEZS-108 in castration- and taxane-resistant prostate cancer. Poster presentation [abstract #294]. At ESMO Congress; 24 September 2011; Stockholm
   Google Scholar
• A phase I/II trial of AEZS-108 in urothelial cancer patients who failed platinum-chemotherapy. Available from: http://clinicaltrials.gov/ct2/show/NCT01234519?term=azes+108&rank=2, 2011
   Google Scholar
• American Cancer Society. Cancer Facts & Figures 2011. American Cancer Society, Atlanta; 2011
   Google Scholar
• Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010;46(4):765-81
   PubMed Web of Science ®Google Scholar
• Reis-Filho JS, Tutt AN. Triple negative tumours: a critical review. Histopathology 2008;52(1):108-18
   PubMed Web of Science ®Google Scholar
• Berger ER. Treatment options for the advanced asymptomatic prostate cancer patient: an active immunotherapy approach. Community Oncol 2007;4(7):447-51
   Google Scholar
• Mathew J, Perez EA. Trastuzumab emtansine in human epidermal growth factor receptor 2-positive breast cancer: a review. Curr Opin Oncol 2011;23(6):594-600
   PubMed Web of Science ®Google Scholar